Patents by Inventor S. Tarran Jones
S. Tarran Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8926971Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: June 20, 2012Date of Patent: January 6, 2015Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20130071381Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: June 20, 2012Publication date: March 21, 2013Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Patent number: 8227211Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: September 23, 2008Date of Patent: July 24, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20090191192Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: September 23, 2008Publication date: July 30, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Patent number: 7566450Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: October 26, 2007Date of Patent: July 28, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20090169541Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: October 26, 2007Publication date: July 2, 2009Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20090142339Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: October 26, 2007Publication date: June 4, 2009Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20090011464Abstract: The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for ?4?7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for ?4?7 integrin. The invention also relates to expression vectors and host cells comprising a nucleotide sequence which encodes a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for ?4?7. The invention further relates to methods of preparing a humanized immunoglobulin, humanized immunoglobulin heavy chain and humanized immunoglobulin light chain that has binding specificity for ?4?7 integrin.Type: ApplicationFiled: June 18, 2008Publication date: January 8, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman, Jose Saldanha, Mary M. Bendig
-
Patent number: 7473421Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: January 27, 2004Date of Patent: January 6, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20080268536Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: October 25, 2007Publication date: October 30, 2008Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Patent number: 7442775Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: January 27, 2004Date of Patent: October 28, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20080241923Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: October 25, 2007Publication date: October 2, 2008Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20080241136Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: October 26, 2007Publication date: October 2, 2008Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Gregory J. LaRosa, Christopher J. Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Patent number: 7402410Abstract: The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for ?4?7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for ?4?7 integrin. The invention also relates to expression vectors and host cells comprising a nucleotide sequence which encodes a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for ?4?7. The invention further relates to methods of preparing a humanized immunoglobulin, humanized immunoglobulin heavy chain and humanized immunoglobulin light chain that has binding specificity for ?4?7 integrin.Type: GrantFiled: August 28, 2006Date of Patent: July 22, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman, José Saldanha, Mary M. Bendig
-
Patent number: 7147851Abstract: The present invention relates to humanized immunoglobulins having binding specificity for ?4?7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can compete with murine Act-1 for binding to human ?4?7 integrin. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin comprises each of the complementarity determining regions of the light and heavy chains of the murine Act-1 antibody.Type: GrantFiled: August 15, 1996Date of Patent: December 12, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman, José Saldanha, Mary M. Bendig
-
Publication number: 20040132980Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: January 27, 2004Publication date: July 8, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20040126851Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: January 27, 2004Publication date: July 1, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Patent number: 6727349Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: February 3, 2000Date of Patent: April 27, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Patent number: 6696550Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: April 23, 2001Date of Patent: February 24, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Publication number: 20020150576Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: April 23, 2001Publication date: October 17, 2002Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe